The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans

This publication has 70 references indexed in Scilit:

• Active transport of the angiotensin‐II antagonist losartan and its main metabolite EXP 3174 across MDCK‐MDR1 and Caco‐2 cell monolayers
  British Journal of Pharmacology, 2000
• BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
  Annual Review of Pharmacology and Toxicology, 1999
• The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.
  Journal of Clinical Investigation, 1998
• Effect of the P-glycoprotein inhibitor, SDZ PSC 833, on the blood and brain pharmacokinetics of colchicine
  Life Sciences, 1997
• P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.
  Journal of Clinical Investigation, 1996
• Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.
  Journal of Clinical Investigation, 1995
• Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
  Published by Elsevier ,1994
• P‐glycoprotein‐mediated transcellular transport of MDR‐reversing agents
  FEBS Letters, 1993
• BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTER
  Annual Review of Biochemistry, 1993
• Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues.
  Journal of Histochemistry & Cytochemistry, 1990